Immune Therapy of Melanoma: Overview of Therapeutic Vaccines Publisher Pubmed



Payandeh Z¹ ; Yarahmadi M² ; Narimansalehfam Z³ ; Tarhriz V⁴ ; Islami M⁵ ; Aghdam AM⁶ ; Eyvazi S^{7, 8}
Source: Journal of Cellular Physiology Published:2019

Abstract

Melanoma is the most serious type of skin cancer which develops from the occurrence of genetic mutations in the melanocytes. Based on the features of melanoma tumors such as location, genetic profile and stage, there are several therapeutic strategies including surgery, chemotherapy, and radiotherapy. However, because of the appearance resistance mechanisms, the efficiency of these treatments strategies may be reduced. It has been demonstrated that therapeutic monoclonal antibodies can improve the efficiency of melanoma therapies. Recently, several mAbs, such as nivolumab, pembrolizumab, and ipilimumab, were approved for the immunotherapy of melanoma. The antibodies inhibit immune checkpoint receptors such as CTL4 and pd-1. Another therapeutic strategy for the treatment of melanoma is cancer vaccines, which improve clinical outcomes in patients. The combination therapy using antibodies and gene vaccine give us a new perspective in the treatment of melanoma patients. Herein, we present the recent progressions in the melanoma immunotherapy, especially dendritic cells mRNA vaccines by reviewing recent literature. © 2019 Wiley Periodicals, Inc.